Targeting Cancer Survival System
Short RNA Therapeutics Target Cancer’s Survival Networks:
The Future of Cancer Therapy
NUAgo develops single-construct short RNAs that target dozens of survival-critical genes, disrupting survival gene networks and collapsing cancer’s survival system.
50%
of people get cancer
90%
of cancers are solid tumors
Under 85%
of solid cancer patients are not eligible for targeted therapies
90%
of targeted therapies fail
Current therapies target individual mutations, components, or pathways.
NUAgo targets the system cancer cells depend on to survive.
What We Do
NUAgo develops sRNA-based cancer therapies that target the systems cancer cells depend on to survive. Our single-construct short RNAs simultaneously suppress multiple survival genes rather than a single target or mutation. This approach does not depend on a specific mutation or pathway. NUAgo’s technology targets multiple survival genes to disrupt cancer’s survival networks and trigger a coordinated cell death response. This system-level approach is designed to overcome treatment resistance and expand treatment beyond the subset of patients eligible for targeted therapies.
Our Mission
Build an innovative biotechnology company focused on treating cancer through regulation of
interconnected genes.
Our Vision
Cure intractable diseases
through translational
regulation.
Our Science
NUAgo’s short RNA (sRNA) platform targets interconnected survival gene networks through RNA interference (RNAi). Built on the scientific discoveries of the company’s co-founders, the platform’s single-construct sRNAs simultaneously suppress multiple survival genes and supports development of tumor-specific therapeutic programs.
Our Pipeline
Our two classes of sRNAs represent a new RNAi modality with both siRNA and miRNA-like activity and tumor-specific selectivity. These sRNAs target multiple survival genes through RNA interference (RNAi). Class 1 sRNAs are 19nt RNAs containing a 6nt seed sequence that drives the sRNA’s biological activity. Class 2 sRNAs are CAG trinucleotide repeat RNAs with known tumor-suppressive activity in humans.
Latest News & Upcoming Events
Persist, Adapt, Resist: Has Cancer Met its Match in Small RNAs?
Technology Networks explores how small RNA therapeutics could counter cancer’s ability to persist, adapt, and resist. NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., describes
Read Article
Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking
NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., speaks with Advancing RNA about why RNAi-based oncology must move beyond single-target thinking, explaining that solid tumors
Read Article
Targeting Cancer Survival Genes in Solid Tumors
NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., joins Daniel Levine on The Bio Report to discuss short RNA constructs that silence multiple cancer survival
Read Article